TY - JOUR
T1 - Sulfonylureas correct trafficking defects of disease-causing ATP-sensitive potassium channels by binding to the channel complex
AU - Yan, Fei Fei
AU - Casey, Jillene
AU - Shyng, Show Ling
PY - 2006/11/3
Y1 - 2006/11/3
N2 - ATP-sensitive potassium (KATP) channels mediate glucose-induced insulin secretion by coupling metabolic signals to β-cell membrane potential and the secretory machinery. Reduced KATP channel expression caused by mutations in the channel proteins: sulfonylurea receptor 1 (SUR1) and Kir6.2, results in loss of channel function as seen in congenital hyperinsulinism. Previously, we reported that sulfonylureas, oral hypoglycemic drugs widely used to treat type II diabetes, correct the endoplasmic reticulum to the plasma membrane trafficking defect caused by two SUR1 mutations, A116P and V187D. In this study, we investigated the mechanism by which sulfonylureas rescue these mutants. We found that glinides, another class of SUR-binding hypoglycemic drugs, also markedly increased surface expression of the trafficking mutants. Attenuating or abolishing the ability of mutant SUR1 to bind sulfonylureas or glinides by the following mutations: Y230A, S1238Y, or both, accordingly diminished the rescuing effects of the drugs. Interestingly, rescue of the trafficking defects requires mutant SUR1 to be co-expressed with Kir6.2, suggesting that the channel complex, rather than SUR1 alone, is the drug target. Observations that sulfonylureas also reverse trafficking defects caused by neonatal diabetes-associated Kir6.2 mutations in a way that is dependent on intact sulfonylurea binding sites in SUR1 further support this notion. Our results provide insight into the mechanistic and structural basis on which sulfonylureas rescue KATP channel surface expression defects caused by channel mutations.
AB - ATP-sensitive potassium (KATP) channels mediate glucose-induced insulin secretion by coupling metabolic signals to β-cell membrane potential and the secretory machinery. Reduced KATP channel expression caused by mutations in the channel proteins: sulfonylurea receptor 1 (SUR1) and Kir6.2, results in loss of channel function as seen in congenital hyperinsulinism. Previously, we reported that sulfonylureas, oral hypoglycemic drugs widely used to treat type II diabetes, correct the endoplasmic reticulum to the plasma membrane trafficking defect caused by two SUR1 mutations, A116P and V187D. In this study, we investigated the mechanism by which sulfonylureas rescue these mutants. We found that glinides, another class of SUR-binding hypoglycemic drugs, also markedly increased surface expression of the trafficking mutants. Attenuating or abolishing the ability of mutant SUR1 to bind sulfonylureas or glinides by the following mutations: Y230A, S1238Y, or both, accordingly diminished the rescuing effects of the drugs. Interestingly, rescue of the trafficking defects requires mutant SUR1 to be co-expressed with Kir6.2, suggesting that the channel complex, rather than SUR1 alone, is the drug target. Observations that sulfonylureas also reverse trafficking defects caused by neonatal diabetes-associated Kir6.2 mutations in a way that is dependent on intact sulfonylurea binding sites in SUR1 further support this notion. Our results provide insight into the mechanistic and structural basis on which sulfonylureas rescue KATP channel surface expression defects caused by channel mutations.
UR - http://www.scopus.com/inward/record.url?scp=33845986742&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845986742&partnerID=8YFLogxK
U2 - 10.1074/jbc.M605195200
DO - 10.1074/jbc.M605195200
M3 - Article
C2 - 16956886
AN - SCOPUS:33845986742
SN - 0021-9258
VL - 281
SP - 33403
EP - 33413
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
IS - 44
ER -